Product Datasheet

Cytokeratin 17 Antibody (SPM560) [DyLight 405] NBP2-34425V

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-34425V

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP2-34425V



NBP2-34425V

Cytokeratin 17 Antibody (SPM560) [DyLight 405]

Unit Size	-	-7 [- 79
Concentration Please see the vial label for concentration. If unlisted please contact technical services. Storage Store at 4C in the dark. Clonality Monoclonal Clone SPM560 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate DyLight 405 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex spithelial but not in stratified or simple epithelial. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish moppithelial cells from luminal epithelium of various glands such as mammary, sweat and sallvary. CK17 is expressed in the pushed in a papendages. It may be considered as 'epithelial stem cell 'marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, 63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated fung carcinoma. CK17 is expressed in specially for poorly-differentiation of the friple negative carcinoma simple negative tumor. Eighty-five percent of the triple negative carcinoma simple negative immore activity represents pancreatoilialiny subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Product Information	
Storage Store at 4C in the dark. Clonality Monoclonal Clone SPM560 Preservative 0.05%, Sodium Azide Isotype IgG2b Kappa Conjugate DyLight 405 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Host Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or sample epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguished. CK17 is expressed in the unit all bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguished. CK17 is expressed in pithelial cells from luminal epithelium of various glands such as mammary, sweat and sallvary. CK17 is expressed in pithelial cells for avirous origins, such as bronchial epithelial stem cell "marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between the interest of the triple negative carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative breast carcinomas and progressive clinic negative breast carcinomas and progressive clinic negative breast carcinomas into treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Unit Size	0.1 ml
Clone SPM560 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate DyLight 405 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Host Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nall bed, hair folicile, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in the panel of antibodies against TTF-1, napsin A, CK56, 68, 3 and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Herz, which are defined as triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vumor. Eighty-five percent of the triple negative brea	Concentration	·
Clone SPM560 Preservative 0.05% Sodium Azide Isotype IgGZb Kappa OpLight 405 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Host Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IPPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycepithelial cells from luminal epithelium of various glands such as mammany, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial role and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, 683, and SCX-2 for diagnostic differentiation between lung adenocarcinoma (LADC), and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as tipne negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampulary cancer, intestinal by pancreatobiliary is very important for treatment. Usually anti-CK17 and anti-MUC1 and	Storage	Store at 4C in the dark.
Preservative 19G2b Kappa	Clonality	Monoclonal
IgG2b Kappa	Clone	SPM560
Conjugate DyLight 405 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate fillament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial setem cell "marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SCX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinomas with expression of CK17 show an aggressive clinical course. The histologic differentiation of treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CUX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Preservative	0.05% Sodium Azide
Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Host Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsis A, CK65, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliar	Isotype	IgG2b Kappa
Product Description	Conjugate	DyLight 405
Product Description This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Specificity/Sensitivity Cytokeratin 17 (Ck17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Ck17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to Ck17 is an excellent tool to distinguish myoepithelial cells from luminal epitheliar on excellent tool to distinguish myoepithelial cells from luminal epitheliar on excellent tool to distinguish myoepithelial cells from luminal epitheliar on excellent tool to distinguish myoepithelial cells from luminal epitheliar on excellent tool to distinguish myoepithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because Ck17 Ab marks basal cell differentiation. Ck17 can be useful when included in a panel of anibodies against TTF-1, napsin A, Ck56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. ck17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative treast carcinomas immunoreact with basal cytokeratins including anti-Ck17. Also important is that cases of triple negative breast carcinomas immunoreact with basal cytokeratins including anti-Ck17. Also important is that cases of triple negative breast carcinomas immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen	Purity	Protein A or G purified
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel oritibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually arti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Buffer	50mM Sodium Borate
wolume of this product. The volume will be greater than or equal to the unit size stated on the datasheet. Mouse Gene ID 3872 Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial stem cell "marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 and anti-CDX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Product Description	
Gene Symbol KRT17 Species Human, Rat, Porcine, Bovine, Goat Marker Basal Epithelial Marker Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Description	volume of this product. The volume will be greater than or equal to the unit size
Species	Host	Mouse
Species	Gene ID	3872
Marker Basal Epithelial Marker Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Gene Symbol	KRT17
Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen Notes	Species	Human, Rat, Porcine, Bovine, Goat
filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. Immunogen The cytoskeletal fraction of rat colon epithelium	Marker	Basal Epithelial Marker
Notes	Specificity/Sensitivity	filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2
	Immunogen	The cytoskeletal fraction of rat colon epithelium
- ,g titli o a tradoniant of friends front oblitino inolatio debutation.	Notes	DvLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries



Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready
Recommended Dilutions	Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, CyTOF-ready





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP2-34425V

NBP1-43317V Mouse IgG2b Kappa Light Chain Isotype Control (MG2b) [DyLight 405]

NBP2-51594-0.1mg Recombinant Human Cytokeratin 17 His Protein

H00003872-T01 Cytokeratin 17 293T Cell Transient Overexpression Lysate

MAB1417 Insulin Antibody (182410) [Unconjugated]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-34425V

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

